Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 1;9(11):e003554. doi: 10.1136/jitc-2021-003554

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Pathological response to preoperative short-course radiotherapy followed by CAPOX and camrelizumab. (A) Radiological and pathological response from patient 7. Left: MRI of the abdomen (upper row) and endoscopic imaging of the primary tumor (lower row) before and after treatment. Right: Postoperative specimen with mucosal retraction at the tumor site with a polypoid structure (upper row) and H&E staining showing CR of the primary tumor after treatment (lower row). (B) Representative CD8 and CD4 staining of pretreatment and posttreatment specimens of patient 7 and patient 12. Scale bars, 250 µm.